Prolia Drug Class and Documentation
Prolia (denosumab) is a RANK ligand (RANKL) inhibitor—a fully human monoclonal antibody that functions as an antiresorptive agent for osteoporosis treatment. 1, 2
Drug Classification
Denosumab is classified as:
- Primary class: RANK ligand (RANKL) inhibitor / monoclonal antibody
- Functional class: Antiresorptive agent (bone resorption inhibitor)
- Mechanism: Binds to RANKL, preventing it from activating RANK receptors on osteoclasts, thereby inhibiting osteoclast formation, function, and survival 2, 3
This distinguishes it from bisphosphonates (which incorporate into bone) and makes it the first biologic antiresorptive therapy for osteoporosis 2.
Documentation Requirements
Essential Elements to Document:
Indication and Risk Assessment:
- Document specific indication: postmenopausal osteoporosis at high risk for fracture 1
- Record fracture risk factors (prior fractures, T-scores, age, multiple vertebral fractures)
- Note if patient is bisphosphonate-intolerant or has contraindications to other therapies 1
Dosing Schedule:
- Standard dose: 60 mg subcutaneously every 6 months 1
- Document exact administration dates—timing is critical as effects reverse after 6 months 1
- Critical: Note that drug holidays or treatment interruptions are NOT recommended with denosumab 1
Pre-treatment Requirements:
- Dental evaluation completed (to assess osteonecrosis of jaw risk) 4
- Vitamin D status checked and deficiency corrected 4
- Baseline serum calcium documented
- Renal function assessed (denosumab has no dose adjustment for renal impairment, but hypocalcemia risk increases) 5, 1
Ongoing Monitoring:
- Calcium and vitamin D supplementation prescribed 4
- Plan for fracture risk reassessment at 5-10 years 1
- Discontinuation plan: Must document transition to bisphosphonate therapy if stopping denosumab to prevent rebound bone loss and vertebral fractures 1, 4
Critical Documentation Pitfall:
Never document denosumab discontinuation without a sequential antiresorptive plan. Stopping denosumab without transitioning to bisphosphonates, hormone therapy, or SERMs causes rapid bone turnover rebound, BMD loss, and up to 20% risk of multiple vertebral fractures 1, 6. Document the specific follow-up antiresorptive agent (typically zoledronic acid or alendronate) before any planned discontinuation 4.
Sample Documentation Template:
"Prolia (denosumab) 60 mg subcutaneous injection initiated for postmenopausal osteoporosis with high fracture risk [specify: prior vertebral fracture/T-score -3.2/multiple risk factors]. Pre-treatment dental evaluation completed [date], vitamin D repleted to >30 ng/mL, baseline calcium 9.2 mg/dL. Patient counseled on 6-month dosing schedule (next dose due [date]), calcium 1200 mg + vitamin D 800-1000 IU daily prescribed. Plan for fracture risk reassessment at 5 years. If discontinuation considered, will transition to bisphosphonate therapy to prevent rebound effect."